Ceftriaxone

Generic Name: Ceftriaxone

Brand Names: Rocephin

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₁₈N_₈O_₇S_₃

CAS Number: 73384-59-5

Unique Ingredient Identifier: 75J73V1629

Background: Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic. It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges, eyes, and inner ear. Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S...

Indication: Ceftriaxone is used for the treatment of the infections (respiratory, skin, soft tissue, UTI, ENT) caused by susceptible organisms. Organisms that are generally susceptible to ceftriaxone include S. pneumoniae, S. pyogenes (group A beta-hemolytic streptococci), coagulase-negative staphylococci, Some Enterobacter spp, H. influenzae, N. gonorrhoeae, P. mirabil...

Associated Conditions: Abscess Brain, Bacterial Endocarditis, Bacterial Infections, Bacterial Sinusitis, Bone and Joint Infections, Chancroid, Community Acquired Pneumonia (CAP), Conjunctivitis gonococcal neonatal, Epididymitis, Epiglottitis, Gonococcal arthritis, Gonococcal infection of pharynx, Gonococcal pelvic inflammatory disease, Intraabdominal Infections, Lower respiratory tract infection bacterial, Lyme Neuroborreliosis, Meningitis, Bacterial, Ophthalmia neonatorum due to gonococcus, Postoperative Infections, Prosthetic Joint Infections, Sepsis Bacterial, Septic Arthritis, Shigellosis, Skin and Subcutaneous Tissue Bacterial Infections, Syphilis, Vulvovaginitis gonococcal, Whipple Disease, Bacterial otitis media, Complicated Urinary Tract Infection caused by susceptible bacteria, Disease caused by Salmonella typhi, Susceptible Bacterial Infections, Uncomplicated Gonorrhea, Uncomplicated Urinary tract infection bacterial

Associated Therapies: -

Clinical Trials

Antimicrobial Treatment in Patients With Ventilator-associated Tracheobronchitis

Phase 4

Conditions: Critical Illness
Mechanical Ventilation Complication

Interventions: Drug: placebo
Drug: ceftriaxone
Drug: ciprofloxacin
Drug: imipenem
Drug: linezolid

First Posted Date: 2017-01-06

Last Posted Date: 2022-08-17

Lead Sponsor: University Hospital, Lille

Target Recruit Count: 154

Registration Number: NCT03012360

Locations: 🇫🇷
Hôpital Roger Salengro, CHRU, Lille, France

Antimicrobial Prophylaxis for Skin Colonization With Propionibacterium Acnes in Primary Open Shoulder Surgery

Not Applicable

Recruiting

Conditions: Propionibacterium Infection

Interventions: Drug: Cefazolin
Drug: Ceftriaxone

First Posted Date: 2016-12-19

Last Posted Date: 2023-05-10

Lead Sponsor: Université de Montréal

Target Recruit Count: 88

Registration Number: NCT02996656

Locations: 🇨🇦
Hôpital du Sacré-Cœur de Montréal, Montréal, Quebec, Canada

Optimising Antibiotic Treatment for Sick Malnourished Children

Phase 2

Conditions: Malnutrition

Interventions: Drug: Ceftriaxone
Drug: Metronidazole

First Posted Date: 2016-04-21

Last Posted Date: 2017-07-02

Lead Sponsor: University of Oxford

Target Recruit Count: 81

Registration Number: NCT02746276

Locations: 🇰🇪
KEMRI WT Clinical Trials Facility, Kilifi, Kenya

The Optimal Time for Intravenous Antibiotic Prophylaxis in Elective Cesarean Section

Phase 2

Conditions: Endometritis

Interventions: Drug: ceftriaxone

First Posted Date: 2016-04-19

Last Posted Date: 2016-04-19

Lead Sponsor: Cairo University

Target Recruit Count: 600

Registration Number: NCT02742948

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Phase 3

Recruiting

Conditions: Community-acquired Pneumonia, Influenza, COVID-19

Interventions: Other: No systemic corticosteroid
Other: No antiviral agent for COVID-19
Other: No immune modulation for COVID-19
Drug: Standard course macrolide
Other: No antiviral agent for influenza
Drug: Local standard venous thromboprophylaxis
Other: No immunoglobulin
Other: No simvastatin
Other: No cysteamine
Other: No Immune Modulator for Influenza
Other: No vitamin C
Other: No antiplatelet
Procedure: Clinician-preferred mechanical ventilation strategy
Other: No renin-angiotensin system inhibitor
Other: No endothelial modulator
Drug: Ceftriaxone
Drug: Moxifloxacin or Levofloxacin
Drug: Extended course macrolide
Drug: Fixed-duration Hydrocortisone
Drug: Five-days oseltamivir
Drug: Lopinavir / Ritonavir
Biological: Convalescent plasma
Drug: Angiotensin converting enzyme inhibitor
Drug: Nirmatrelvir/ritonavir
Drug: Therapeutic dose anticoagulation
Procedure: Protocolised mechanical ventilation strategy
Drug: Interferon beta-1a
Drug: Vitamin C
Drug: Simvastatin
Drug: Aspirin
Drug: Eritoran
Drug: Cysteamine
Drug: Imatinib
Drug: Shock-dependent hydrocortisone
Drug: Ten-days oseltamivir
Drug: P2Y12 inhibitor
Drug: Angiotensin Receptor Blockers
Drug: Conventional low dose thromboprophylaxis
Biological: Delayed administration of convalescent plasma
Drug: Piperacillin-tazobactam
Drug: Hydroxychloroquine
Drug: Anakinra
Drug: Apremilast
Drug: Baricitinib
Drug: Remdesivir
Drug: Fixed-duration higher dose Hydrocortisone
Drug: Hydroxychloroquine + lopinavir/ritonavir
Drug: Intermediate dose thromboprophylaxis
Drug: Nirmatrelvir/ritonavir + remdesivir
Drug: ARB + DMX-200
Drug: Ceftaroline
Drug: Baloxavir Marboxil
Drug: Tocilizumab
Drug: Amoxicillin-clavulanate
Drug: Fixed-duration dexamethasone
Drug: Five-days oseltamivir + baloxavir marboxil
Drug: Continuation of therapeutic dose anticoagulation
Drug: Ivermectin
Drug: Sarilumab
Drug: Ten-days oseltamivir + baloxavir marboxil

First Posted Date: 2016-04-13

Last Posted Date: 2024-07-12

Lead Sponsor: UMC Utrecht

Target Recruit Count: 20000

Registration Number: NCT02735707

Locations: 🇨🇦
Toronto Western Hospital, Toronto, Ontario, Canada
🇺🇸
University of Illinois Health, Chicago, Illinois, United States
🇦🇺
Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia

and more 405 locations

Impact of the Choice of 3rd Generation Cephalosporins on the Emergence of Resistance in the Microbiota Intestinal.

Phase 3

Completed

Conditions: Emergence of Bacterial Resistance to Antibiotics

Interventions: Drug: ceftriaxone
Drug: Cefotaxime

First Posted Date: 2016-01-20

Last Posted Date: 2018-05-21

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 22

Registration Number: NCT02659033

Locations: 🇫🇷
Hôpital Bichat, Paris, France

Crossover Study to Compare the Pharmacokinetics of Subcutaneous and Intravenous Ceftriaxone Administration

Phase 2

Completed

Conditions: Pharmacokinetics in Healthy Adults

Interventions: Drug: ceftriaxone

First Posted Date: 2015-09-28

Last Posted Date: 2017-04-25

Lead Sponsor: scPharmaceuticals, Inc.

Target Recruit Count: 18

Registration Number: NCT02561442

Samu Save Sepsis: Early Goal Directed Therapy in Pre Hospital Care of Patients With Severe Sepsis and/or Septic Shock

Phase 3

Completed

Conditions: Severe Septic Syndrome (Severe Sepsis and Septic Shock) Diagnosed and Treated by Mobile Intensive Care Unit

Interventions: Drug: Ceftriaxone
Drug: Piperacillin tazobactam
Drug: Norepinephrine
Drug: Hydrocortisone

First Posted Date: 2015-06-16

Last Posted Date: 2023-03-07

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 398

Registration Number: NCT02473263

Locations: 🇫🇷
Anesthesiology, Intensive Care Unit and emergency department - Necker Hospital, Paris, France

A Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftriaxone In Adults With an Ileostomy

Phase 1

Completed

Conditions: Healthy Volunteers With Ileostomy

Interventions: Drug: SYN-004
Drug: Esomeprazole
Drug: Ceftriaxone

First Posted Date: 2015-06-16

Last Posted Date: 2018-11-27

Lead Sponsor: Theriva Biologics, Inc.

Target Recruit Count: 15

Registration Number: NCT02473640

Locations: 🇨🇦
Synthetic Biologics Investigative Site, Montreal, Canada

Is Spontaneous Bacterial Peritonitis Still Responding to 3rd Generation Cephalosporins?

Phase 3

Conditions: Primary Bacterial Peritonitis

Interventions: Drug: ceftriaxone
Drug: Cefotaxime

First Posted Date: 2015-05-13

Last Posted Date: 2017-06-20

Lead Sponsor: Tanta University

Target Recruit Count: 100

Registration Number: NCT02443285

Locations: 🇪🇬
Tanta university - faculty of medicine, Cairo, Egypt

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy